Skip to main content
. 2020 Mar 20;38(5):1618–1626. doi: 10.1007/s10637-020-00922-5

Fig. 4.

Fig. 4

Circulating lymphocytes detected in peripheral blood 23 days after treatment initiation in animals with a single Renca tumor. a Similar levels of CD45+ leucocytes were detected in all samples. b NanoDoce treatments administered IT/PT significantly increased circulating CD4+ T cells. c IV docetaxel and NanoDoce treatments significantly increased circulating CD8+ T cells. d IT/PT NanoDoce treatments resulted in increased in circulating Treg cells. Although there was trend toward reduction following IT NanoDoce treatment, no significant differences in circulating populations of macrophages (M1 (e) and M2 (f)) or MDSCs (g) were detected in docetaxel or NanoDoce treatments compared to IT vehicle. Graphs show individual animal samples with center lines = means and error bars = ± Std. dev. Statistically significant differences vs. IT vehicle control are as follows: ‡ = p < 0.0001; * = p < 0.001